CG
TGTX icon

Cutler Group’s TG Therapeutics TGTX Stock Holding History

Cutler Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,080
Closed -$33.1K – 3570
2023
Q4 		$35K Sell
2,080
-2,720
-57% -$31.6K ﹤0.01% 1659
2023
Q3 		$40K Buy
4,800
+4,000
+500% +$55.8K ﹤0.01% 1631
2023
Q2 		$19K Buy
800
+300
+60% +$7.75K ﹤0.01% 1885
2023
Q1 		$7K Hold
500
– – ﹤0.01% 2575
2022
Q4 		$5K Hold
500
– – ﹤0.01% 3215
2022
Q3 		$2K Hold
500
– – ﹤0.01% 4307
2022
Q2 		$2K Sell
500
-5,637
-92% -$35.2K ﹤0.01% 4381
2022
Q1 		$58K Buy
6,137
+4,717
+332% +$54.6K ﹤0.01% 2133
2021
Q4 		$26K Sell
1,420
-2,820
-67% -$73.2K ﹤0.01% 2926
2021
Q3 		$141K Buy
4,240
+2,240
+112% +$69.3K 0.01% 1627
2021
Q2 		$77K Buy
+2,000
New +$78.5K ﹤0.01% 2106
2021
Q1 		– Sell
-1,249
Closed -$60K – 6282
2020
Q4 		$64K Buy
+1,249
New +$42.2K ﹤0.01% 1823
2020
Q3 		– Sell
-6,600
Closed -$152K – 5253
2020
Q2 		$128K Buy
+6,600
New +$106K 0.01% 1148
2019
Q1 		– Sell
-44
Closed -$238 – 4745
2018
Q4 		$0 Sell
44
-4,400
-99% -$21.9K ﹤0.01% 4569
2018
Q3 		$24K Buy
4,444
+4,400
+10,000% +$50.3K ﹤0.01% 2125
2018
Q2 		$0 Sell
44
-2,600
-98% -$35.8K ﹤0.01% 4881
2018
Q1 		$37K Sell
2,644
-1,782
-40% -$22.8K ﹤0.01% 1878
2017
Q4 		$36K Buy
4,426
+222
+5% +$1.94K ﹤0.01% 2120
2017
Q3 		$49K Buy
4,204
+3,013
+253% +$34.3K ﹤0.01% 2262
2017
Q2 		$11K Sell
1,191
-6,729
-85% -$75.3K ﹤0.01% 4088
2017
Q1 		$92K Buy
7,920
+7,520
+1,880% +$54K ﹤0.01% 1822
2016
Q4 		$1K Hold
400
– – ﹤0.01% 6151
2016
Q3 		$3K Hold
400
– – ﹤0.01% 5455
2016
Q2 		$2K Sell
400
-3,651
-90% -$29.7K ﹤0.01% 5755
2016
Q1 		$34K Buy
4,051
+1,651
+69% +$14.4K ﹤0.01% 2728
2015
Q4 		$28K Buy
+2,400
New +$30.3K ﹤0.01% 3067

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's TGTX Position: Q1 2024 in Review

Cutler Group sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 2,080 shares — an estimated $33.1K sold.

Cutler Group first reported a position in TGTX in Q4 2015 and held it in 26 quarters. The position peaked at $141K in Q3 2021. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Cutler Group reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 2,080 TG Therapeutics shares in Q1 2024, an estimated $33.1K.
  • Cutler Group first reported a position in TG Therapeutics in Q4 2015 and held it in 26 quarters.
  • Cutler Group's TG Therapeutics position peaked at $141K in Q3 2021.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.